Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 inact mut MK-1775 + Carboplatin + Paclitaxel ovarian cancer sensitive detail...
TP53 wild-type Ad.p53-DC vaccine ovarian cancer predicted - sensitive detail...
TP53 wild-type p53-SLP vaccine ovarian cancer no benefit detail...
Unknown unknown ENMD-2076 ovarian cancer not applicable detail...
MET positive Altiratinib ovarian cancer predicted - sensitive detail...
Unknown unknown Nintedanib ovarian cancer not applicable detail...
KRAS mutant Alpelisib + Binimetinib ovarian cancer sensitive detail...
Unknown unknown MLN4924 ovarian cancer not applicable detail...
Unknown unknown Cediranib + Olaparib ovarian cancer not applicable detail...
Unknown unknown Docetaxel + Vandetanib ovarian cancer no benefit detail...
Unknown unknown Cabozantinib ovarian cancer not applicable detail...
Unknown unknown Axitinib + Paclitaxel + Carboplatin ovarian cancer not applicable detail...
Unknown unknown Itraconazole ovarian cancer not applicable detail...
Unknown unknown Vistusertib + Paclitaxel ovarian cancer not applicable detail...
Unknown unknown Sunitinib ovarian cancer not applicable detail...
Unknown unknown Abemaciclib ovarian cancer not applicable detail...
Unknown unknown VS-5584 ovarian cancer not applicable detail...
HRAS mutant Alpelisib + Binimetinib ovarian cancer predicted - sensitive detail...
Unknown unknown BKM120 + Trametinib ovarian cancer not applicable detail...
BRCA1 inact mut Niraparib ovarian cancer sensitive detail...
BRCA2 mutant Olaparib ovarian cancer sensitive detail...
BRCA1 mutant Olaparib ovarian cancer sensitive detail...
Unknown unknown REGN421 ovarian cancer not applicable detail...
ARID1A mutant GSK126 ovarian cancer sensitive detail...
KRAS mutant CI-1040 ovarian cancer sensitive detail...
BRAF V600E CI-1040 ovarian cancer sensitive detail...
ARID1A dec exp GSK126 ovarian cancer sensitive detail...
ARID1A mutant UNC1999 ovarian cancer sensitive detail...
ARID1A wild-type GSK126 ovarian cancer no benefit detail...
Unknown unknown Nintedanib + Carboplatin + Paclitaxel ovarian cancer not applicable detail...
Unknown unknown GSK2141795 + Cisplatin ovarian cancer not applicable detail...
Unknown unknown Conatumumab + Ganitumab ovarian cancer not applicable detail...
TP53 R248Q ReACp53 ovarian cancer sensitive detail...
TP53 R248Q APR-246 + Cisplatin ovarian cancer sensitive detail...
TP53 loss ReACp53 ovarian cancer no benefit detail...
Unknown unknown RO5520985 ovarian cancer not applicable detail...
ARID1A dec exp Talazoparib ovarian cancer sensitive detail...
TP53 loss LB-100 + Cisplatin ovarian cancer sensitive detail...
TP53 inact mut LB-100 + Cisplatin ovarian cancer sensitive detail...
Unknown unknown LB-100 + Cisplatin ovarian cancer not applicable detail...
Unknown unknown AZD1480 ovarian cancer not applicable detail...
Unknown unknown SST0116CL1 ovarian cancer not applicable detail...
BRAF N486_P490del LY3009120 ovarian cancer sensitive detail...
BRAF N486_P490del Trametinib ovarian cancer sensitive detail...
BRAF N486_P490del Vemurafenib ovarian cancer resistant detail...
BRAF N486_P490del Dabrafenib ovarian cancer predicted - resistant detail...
TP53 S241F Ganetespib ovarian cancer sensitive detail...
Unknown unknown JNJ-54302833 ovarian cancer not applicable detail...
Unknown unknown TAK-960 ovarian cancer not applicable detail...
Unknown unknown Bevacizumab ovarian cancer not applicable detail...
Unknown unknown AIM-100 ovarian cancer not applicable detail...
Unknown unknown ST7612AA1 ovarian cancer not applicable detail...
AKT1 wild-type GSK2141795 ovarian cancer predicted - sensitive detail...
TP53 mutant Nutlin-3a ovarian cancer no benefit detail...
TP53 mutant Nutlin-3 + Etoposide ovarian cancer sensitive detail...
TP53 inact mut Nutlin-3 + Cisplatin ovarian cancer sensitive detail...
TP53 del Nutlin-3a ovarian cancer no benefit detail...
TP53 del Nutlin-3 + Cisplatin ovarian cancer sensitive detail...
TP53 del Nutlin-3 + Etoposide ovarian cancer sensitive detail...
Unknown unknown AB61 ovarian cancer not applicable detail...
Unknown unknown BAY1161909 ovarian cancer not applicable detail...
Unknown unknown BAY1217389 ovarian cancer not applicable detail...
Unknown unknown Paclitaxel + TVB-2640 ovarian cancer not applicable detail...
Unknown unknown Vandetanib ovarian cancer no benefit detail...
NRAS mutant Trametinib ovarian cancer sensitive detail...
BRCA1 mut TP53 Y220C Carboplatin + VX-970 ovarian cancer sensitive detail...
Unknown unknown Cisplatin + TRX-E-002-1 ovarian cancer not applicable detail...
Unknown unknown TRX-E-002-1 ovarian cancer not applicable detail...
Unknown unknown Paclitaxel + TRX-E-002-1 ovarian cancer not applicable detail...
BRCA1 inact mut Veliparib + Cyclophosphamide ovarian cancer no benefit detail...
BRCA2 inact mut Veliparib + Cyclophosphamide ovarian cancer no benefit detail...
Unknown unknown Everolimus + Bevacizumab ovarian cancer not applicable detail...
NOTCH1 positive LY3039478 ovarian cancer sensitive detail...
Unknown unknown Napabucasin ovarian cancer not applicable detail...
Unknown unknown Demcizumab ovarian cancer not applicable detail...
Unknown unknown Demcizumab + Paclitaxel ovarian cancer not applicable detail...
Unknown unknown Alisertib ovarian cancer not applicable detail...
Unknown unknown Ipafricept + Carboplatin + Paclitaxel ovarian cancer not applicable detail...
BRCA1 mutant Irinotecan + Veliparib ovarian cancer predicted - sensitive detail...
BRCA2 mutant Irinotecan + Veliparib ovarian cancer predicted - sensitive detail...
FGFR2-FAM76A BGJ398 ovarian cancer sensitive detail...
Unknown unknown Cediranib + Carboplatin ovarian cancer not applicable detail...
ERBB2 positive Hertuzumab-vc-MMAE ovarian cancer sensitive detail...
Unknown unknown Niraparib ovarian cancer not applicable detail...
KRAS mutant OSI-027 ovarian cancer sensitive detail...
PTEN loss OSI-027 ovarian cancer sensitive detail...
BRCA1 mutant Rucaparib ovarian cancer sensitive detail...
BRCA2 mutant Rucaparib ovarian cancer sensitive detail...
BRCA1 mutant Niraparib ovarian cancer predicted - sensitive detail...
BRCA2 mutant Niraparib ovarian cancer predicted - sensitive detail...
BRCA1 wild-type BRCA2 wild-type Niraparib ovarian cancer predicted - sensitive detail...
FGFR2 amp BAY1187982 ovarian cancer sensitive detail...
Unknown unknown ABT-737 + AZD8055 + Trametinib ovarian cancer not applicable detail...
Unknown unknown ABT-737 + BEZ235 + Trametinib ovarian cancer not applicable detail...
Unknown unknown ABT-737 + MK2206 + Trametinib ovarian cancer not applicable detail...
TP53 R280K APR-246 + Cisplatin ovarian cancer sensitive detail...
TP53 P151H APR-246 + Cisplatin ovarian cancer sensitive detail...
TP53 L111Q APR-246 + Cisplatin ovarian cancer sensitive detail...
TP53 Y163H APR-246 + Cisplatin ovarian cancer sensitive detail...
TP53 P278R APR-246 + Cisplatin ovarian cancer sensitive detail...
BRCA1 wild-type Talazoparib + Temozolomide ovarian cancer sensitive detail...
Unknown unknown KPT-185 ovarian cancer not applicable detail...
Unknown unknown Cisplatin + KPT-185 ovarian cancer not applicable detail...
Unknown unknown Selinexor ovarian cancer not applicable detail...
Unknown unknown Cisplatin + Selinexor ovarian cancer not applicable detail...
TP53 R175H NSC319726 ovarian cancer sensitive detail...
Unknown unknown JI-101 ovarian cancer not applicable detail...
Unknown unknown Pegylated liposomal-doxorubicin + Trebananib ovarian cancer not applicable detail...
Unknown unknown Cediranib ovarian cancer not applicable detail...
Unknown unknown PF-06647263 ovarian cancer not applicable detail...
Unknown unknown BGB-A317 + Pamiparib ovarian cancer not applicable detail...
BRCA1 mutant Talazoparib ovarian cancer predicted - sensitive detail...
BRCA2 mutant Talazoparib ovarian cancer predicted - sensitive detail...
Unknown unknown ETP-46464 + Radiotherapy ovarian cancer not applicable detail...
Unknown unknown Cisplatin + ETP-46464 ovarian cancer not applicable detail...
Unknown unknown Carboplatin + ETP-46464 ovarian cancer not applicable detail...
Unknown unknown Cisplatin + VE-821 ovarian cancer not applicable detail...
AKT1 Q79K Capivasertib ovarian cancer sensitive detail...
Unknown unknown S2101 ovarian cancer not applicable detail...
TP53 mutant MK-1775 + Carboplatin ovarian cancer predicted - sensitive detail...
KRAS mut TP53 G105C TP53 V157fs MK-1775 + Carboplatin ovarian cancer predicted - sensitive detail...
BRCA1 mut TP53 E298* MK-1775 + Carboplatin ovarian cancer predicted - sensitive detail...
TP53 Y163* MK-1775 + Carboplatin ovarian cancer predicted - sensitive detail...
TP53 P98fs TP53 R175C TP53 S215G MK-1775 + Carboplatin ovarian cancer predicted - resistant detail...
Unknown unknown Cisplatin + NU6027 ovarian cancer not applicable detail...
TP53 positive NU6027 + Temozolomide ovarian cancer predicted - sensitive detail...
BRCA1 mutant Pamiparib ovarian cancer predicted - sensitive detail...
BRCA2 mutant Pamiparib ovarian cancer predicted - sensitive detail...
Unknown unknown Cediranib + Durvalumab + Olaparib ovarian cancer not applicable detail...
Unknown unknown AZD5363 + Olaparib ovarian cancer not applicable detail...
Unknown unknown Lurbinectedin ovarian cancer not applicable detail...
ERBB2 positive PRS-343 ovarian cancer sensitive detail...
KRAS act mut PD-0325901 + Gedatolisib ovarian cancer predicted - sensitive detail...
Unknown unknown SCH 58500 ovarian cancer not applicable detail...
Unknown unknown Ad5CMV-p53 gene ovarian cancer not applicable detail...
TP53 over exp p53:264-272 vaccine ovarian cancer predicted - sensitive detail...
Unknown unknown C3742 + Cisplatin ovarian cancer not applicable detail...
Unknown unknown PV1019 + Topotecan ovarian cancer not applicable detail...
Unknown unknown Camptothecin + PV1019 ovarian cancer not applicable detail...
BRCA1 E23Vfs*17 BRCA1 T37Qfs*13 Carboplatin ovarian cancer predicted - resistant detail...
BRCA1 E23Vfs*17 BRCA1 E29Sfs*2 BRCA1 K38Sfs*12 Carboplatin ovarian cancer predicted - resistant detail...
ERBB2 mutant Neratinib ovarian cancer no benefit detail...
ERBB2 positive MI130004 ovarian cancer sensitive detail...
ARID1A loss unspecified PD-L1 antibody ovarian cancer predicted - sensitive detail...
Unknown unknown Tisotumab Vedotin ovarian cancer not applicable detail...
Unknown unknown Nivolumab + Varlilumab ovarian cancer not applicable detail...
Unknown unknown MEDI3617 ovarian cancer not applicable detail...
BRCA2 loss APTO-253 ovarian cancer predicted - sensitive detail...
ERBB2 positive ARX-788 ovarian cancer sensitive detail...
Unknown unknown Selumetinib + SHP099 ovarian cancer not applicable detail...
Unknown unknown BAY1000394 ovarian cancer not applicable detail...
ERBB2 amp Pertuzumab + Trastuzumab ovarian cancer predicted - sensitive detail...
ERBB2 over exp Pertuzumab + Trastuzumab ovarian cancer predicted - sensitive detail...
BRAF V600E Vemurafenib ovarian cancer predicted - sensitive detail...
Unknown unknown Avelumab ovarian cancer not applicable detail...
Unknown unknown SNS-032 ovarian cancer not applicable detail...
Unknown unknown SNS-032 + unspecified PD-1 antibody ovarian cancer not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00194714 Phase Ib/II HER2 Vaccine Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab Active, not recruiting
NCT00565851 Phase III Gemcitabine Docetaxel + Paclitaxel Carboplatin Bevacizumab Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Active, not recruiting
NCT00892736 Phase I Veliparib Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy Completed
NCT00993655 Phase III Cisplatin Paclitaxel Carboplatin Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed
NCT01031381 Phase II Everolimus + Bevacizumab Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer Completed
NCT01132014 Phase I Bevacizumab Dacarbazine Autologous OC-DC Vaccine in Ovarian Cancer Completed
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Completed
NCT01248949 Phase I Bevacizumab MEDI3617 Gemcitabine Carboplatin Paclitaxel A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors Completed
NCT01264432 Phase I Veliparib Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer Completed
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed
NCT01292655 Phase I BMS-906024 Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Completed
NCT01305213 Phase Ib/II Fosbretabulin Bevacizumab Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed
NCT01312376 Phase I Fludarabine Cyclophosphamide Bevacizumab CD3/CD28 costimulated vaccine-primed autologous T-cells OC-DC vaccine Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer Unknown status
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Recruiting
NCT01357161 Phase II Carboplatin Adavosertib Paclitaxel A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) Completed
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Suspended
NCT01384253 Phase I 212Pb-TCMC-Trastuzumab + Trastuzumab Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy Completed
NCT01445418 Phase I Olaparib Carboplatin AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer Completed
NCT01459380 Phase I Carboplatin Doxorubicin Veliparib Bevacizumab Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed
NCT01482715 Rucaparib A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) Active, not recruiting
NCT01493505 Phase III Carboplatin Paclitaxel Trebananib TRINOVA-3 Terminated
NCT01551745 Phase II FANG vaccine + Bevacizumab Salvage Ovarian FANG Vaccine + Bevacizumab Completed
NCT01579812 Phase II Metformin Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients Completed
NCT01610206 Phase II Gemcitabine + Pazopanib Gemcitabine A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer Active, not recruiting
NCT01616303 Phase II Oregovomab + Carboplatin + Paclitaxel Paclitaxel + Carboplatin A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer Completed
NCT01621542 Phase I WT2725 Clinical Study of WT2725 in Patients With Advanced Malignancies Completed
NCT01623349 Phase I BYL719 + Olaparib BKM120 + Olaparib Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer Active, not recruiting
NCT01652079 Phase II CRLX101 + Bevacizumab CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer Completed
NCT01663857 Phase Ib/II Ralimetinib Carboplatin + Gemcitabine A Study of LY2228820 for Recurrent Ovarian Cancer Completed
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Recruiting
NCT01831089 Phase I Lurbinectedin + Paclitaxel + Bevacizumab Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed
NCT01847274 Phase III Niraparib A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Completed
NCT01874353 Phase III Olaparib Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Active, not recruiting
NCT01920061 Phase I PF-05212384 + Dacomitinib PF-05212384 + Cisplatin Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents Recruiting
NCT01952249 Phase Ib/II Demcizumab Paclitaxel A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian Terminated
NCT01962948 Phase II Paclitaxel Ganetespib Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Terminated
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Recruiting
NCT01972516 Phase II Tivozanib Tivozanib As Maintenance Therapy In GYN Terminated
NCT01995188 Phase I DNIB0600A + Carboplatin + Bevacizumab DNIB0600A + Carboplatin A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer Completed
NCT01999738 Phase I EC1456 Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Completed
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed
NCT02035345 FDA approved Carboplatin Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated
NCT02046421 Phase I Mifepristone Carboplatin + Gemcitabine Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Completed
NCT02050009 Phase I Paclitaxel + Carboplatin + Metformin Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Withdrawn
NCT02100007 Phase Ib/II ME-344 + Topotecan ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors Terminated
NCT02117817 Phase I BKM120 + Abraxane Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer Withdrawn
NCT02118285 Phase I Aldesleukin Epacadostat Cyclophosphamide Fludarabine Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Completed
NCT02122809 Phase I Chiauranib Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed
NCT02122861 Phase I ID-LV305 A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 Completed
NCT02124421 Phase II Paclitaxel + Carboplatin Cisplatin + Paclitaxel Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer Recruiting
NCT02199171 Phase I Carboplatin Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer Completed
NCT02203513 Phase II Prexasertib Chk1/2 Inhibitor (LY2606368) in Women With BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Non-High Risk Triple Negative Breast Cancer, and Grade Serous Ovarian Cancer at Low Genetic Risk Recruiting
NCT02222922 Phase I Fluconazole PF-06647020 A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors Recruiting
NCT02269293 Phase I Carboplatin + Paclitaxel + Selinexor Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers Recruiting
NCT02298959 Phase I Aflibercept + Pembrolizumab Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors Recruiting
NCT02312245 Phase II Topotecan Doxorubicin Paclitaxel Gemcitabine Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting
NCT02323191 Phase I Atezolizumab LY3022855 A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors Recruiting
NCT02326844 Phase II Talazoparib BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment Terminated
NCT02327078 Phase Ib/II INCB024360 + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Active, not recruiting
NCT02335918 Phase Ib/II Nivolumab + Varlilumab A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Completed
NCT02340611 Phase II Cediranib + Olaparib A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib Completed
NCT02341625 Phase Ib/II BMS-986148 BMS-986148 + Nivolumab A Study of BMS-986148 in Patients With Select Advanced Solid Tumors Active, not recruiting
NCT02346747 Phase II FANG vaccine Phase II/III Trial of Maintenance Vigil for High Risk Stage III/IV Ovarian Cancer (VITAL) Active, not recruiting
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated
NCT02349958 Phase II Mitomycin C Cisplatin Doxorubicin Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Unknown status
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Active, not recruiting
NCT02417753 Phase II AZD9150 AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites Terminated
NCT02419417 Phase Ib/II BMS986158 Paclitaxel Study of BMS-986158 in Subjects With Select Advanced Solid Tumors Recruiting
NCT02432690 Phase II BBI503 A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation Active, not recruiting
NCT02432963 Phase I MVAp53 Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting
NCT02433626 Phase I COTI-2 Study of COTI-2 for the Treatment of Gynecologic Malignancies and Head and Neck Squamous Cell Carcinoma Recruiting
NCT02437812 Phase II Paclitaxel Carboplatin Metformin Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma Recruiting
NCT02446600 Phase III Paclitaxel Doxorubicin Gemcitabine Carboplatin Olaparib Cediranib Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Completed
NCT02452775 Phase I OC-L Autologous OC-L Vaccine and Ovarian Cancer Completed
NCT02476968 FDA approved Olaparib To Assess Efficacy of Olaparib Maintenance Monotherapy at Preventing or Delaying the Return of the Cancer Active, not recruiting
NCT02487095 Phase Ib/II VX-970 Topotecan Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer Recruiting
NCT02498600 Phase II Ipilimumab Nivolumab Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Active, not recruiting
NCT02502266 Phase II Topotecan Paclitaxel Doxorubicin Olaparib Cediranib Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting
NCT02520154 Phase II Paclitaxel + Carboplatin Pembrolizumab Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer Recruiting
NCT02558348 Phase Ib/II Anlotinib Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) Recruiting
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed
NCT02575807 Phase Ib/II Epacadostat CRS-207 Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer Active, not recruiting
NCT02580058 Phase III Doxorubicin Avelumab A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer Active, not recruiting
NCT02584478 Phase Ib/II Anlotinib + Carboplatin + Paclitaxel Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) Recruiting
NCT02595892 Phase II VX-970 Gemcitabine Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting
NCT02606305 Phase I Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer Recruiting
NCT02627430 Phase I Onalespib + Talazoparib Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Withdrawn
NCT02627443 Phase II Carboplatin + Gemcitabine VX-970 Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Recruiting
NCT02631733 Phase I Irinotecan + Veliparib Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Suspended
NCT02631876 Phase II Doxil + Paclitaxel Gemcitabine Topotecan Mirvetuximab Soravtansine PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer Active, not recruiting
NCT02632448 Phase Ib/II LY2880070 + Gemcitabine LY2880070 A Study of LY2880070 in Patients With Advanced or Metastatic Cancer Recruiting
NCT02644369 Phase II Pembrolizumab Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors Active, not recruiting
NCT02646319 Phase II Nab-Rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Active, not recruiting
NCT02649673 Phase Ib/II LCL161 + Topotecan LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies Recruiting
NCT02655016 Phase III Niraparib A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy Active, not recruiting
NCT02657889 Phase Ib/II Niraparib + Pembrolizumab Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162) Active, not recruiting
NCT02658214 Phase I Carboplatin + Gemcitabine Carboplatin + nab-paclitaxel Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Durvalumab + Tremelimumab Paclitaxel + Carboplatin Carboplatin + Etoposide Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors Active, not recruiting
NCT02681237 Phase I Cediranib + Olaparib A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer Recruiting
NCT02693535 Phase II Vemurafenib + Cobimetinib Regorafenib Vismodegib Bosutinib Palbociclib Cetuximab Axitinib Pembrolizumab Temsirolimus Dasatinib Pertuzumab + Trastuzumab Crizotinib Sunitinib Olaparib Erlotinib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Recruiting
NCT02734004 Phase Ib/II Durvalumab + Olaparib A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) Recruiting
NCT02737787 Phase I Nivolumab + WT1 vaccine A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer Active, not recruiting
NCT02760797 Phase I Emactuzumab + RO7009789 A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed
NCT02762981 Phase Ib/II Nab-paclitaxel + Relacorilant Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors Recruiting
NCT02799095 Phase I ALKS 4230 A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors Recruiting
NCT02839707 Phase II Atezolizumab + Bevacizumab + Doxil Atezolizumab + Doxil Doxil + Bevacizamub Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Recruiting
NCT02923349 Phase Ib/II INCAGN01949 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02950064 Phase I BTP-114 A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Active, not recruiting
NCT02952248 Phase I BI 754091 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Recruiting
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Recruiting
NCT02996825 Phase I Mirvetuximab Soravtansine Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer Recruiting
NCT03023319 Phase I Bosutinib + Pemetrexed Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Recruiting
NCT03026062 Phase II Tremelimumab Durvalumab + Tremelimumab Durvalumab Durvalumab and Tremelimumab in Combo Versus Sequential Recruiting
NCT03029598 Phase Ib/II Carboplatin + Pembrolizumab Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting
NCT03030287 Phase I OMP-305B83 + Paclitaxel A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer Active, not recruiting
NCT03056833 Phase I LEE011 + Carboplatin + Paclitaxel Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer Recruiting
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Recruiting
NCT03132922 Phase I Autologous MAGE-A4 C1032 TCR-modified T cells MAGE-A4c1032T for Multi-Tumor Recruiting
NCT03134638 Phase I SY-1365 A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors Recruiting
NCT03150810 Phase Ib/II Pamiparib + Temozolomide Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03154281 Phase I Niraparib + Everolimus Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast Recruiting
NCT03162627 Phase I Olaparib + Selumetinib Selumetinib and Olaparib in Solid Tumors Recruiting
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Recruiting
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Recruiting
NCT03206177 Phase I Carboplatin + Galunisertib + Paclitaxel Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Recruiting
NCT03239145 Phase I Pembrolizumab + Trebananib Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor Recruiting
NCT03283943 Phase I Durvalumab PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. Recruiting
NCT03292172 Phase I Atezolizumab + TEN-010 A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer Suspended
NCT03294694 Phase I Fulvestrant + PDR001 + Ribociclib PDR001 + Ribociclib Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer Recruiting
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Recruiting
NCT03342417 Phase II Nivolumab + Ipilimumab Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients Recruiting
NCT03363776 Phase Ib/II BMS-986277 BMS-986277 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers Recruiting
NCT03449108 Phase II Cyclophosphamide + Fludarabine + IL-12 + LN-145 + Mesna Iovance Alliance: LN-145 Across Multiple Tumor Types Recruiting
NCT03456700 Phase II Auranofin + Sirolimus Auranofin and Sirolimus in Treating Participants With Ovarian Cancer Suspended
NCT03508570 Phase I Nivolumab Nivolumab + Ipilimumab Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03552471 Phase I Mirvetuximab Soravtansine + Rucaparib Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Recruiting
NCT03586661 Phase I Copanlisib + Niraparib Niraparib and Copanlisib in Treating Participants With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Not yet recruiting
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Recruiting
NCT03667716 Phase I COM701 COM701 + Nivolumab COM701 in Subjects With Advanced Solid Tumors Recruiting
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Recruiting
NCT03717415 Phase Ib/II Carboplatin + Rebastinib A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors Recruiting
NCT03719326 Phase I AB928 + Doxil A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies Recruiting
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Recruiting
NCT03784378 Phase Ib/II RXDX-105 Continued Access to RXDX-105 Recruiting
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Recruiting
NCT03872947 Phase I Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 FOLFIRI + TRK-950 A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Not yet recruiting